LAS VEGAS, Oct. 16, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today that, under a March 9, 2007 agreement with Pharmaplaz, Ltd., a private Irish healthcare company, where Samaritan receives $10 million non-refundable upfront money in two payments to develop and commercialize HIV entry inhibitor drug SP-01A, they have received the second upfront payment of $8.6M.
